Galleri

Galleri is a multi-cancer early detection test that uses a single blood draw to screen for over 50 types of cancer. It is recommended for adults aged 50 or older who are at an elevated risk for cancer. Galleri is not a diagnostic test and does not detect all cancers. A positive result requires confirmatory diagnostic evaluation by medically established procedures (e.g., imaging) to confirm cancer.

GRAIL is a healthcare company innovating to solve medicine’s most important challenges. Our team of leading scientists, engineers and clinicians are on an urgent mission to detect cancer early, when it is more treatable and potentially curable. GRAIL's Galleri® test is a first-of-its-kind multi-cancer early detection (MCED) test that can detect a signal shared by more than 50 cancer types and predict the tissue type or organ associated with the signal to help healthcare providers determine next steps.

Freenome is a healthcare company that uses artificial intelligence and multiomics technology to detect cancer in its earliest stages through a simple blood draw. The company's mission is to make early cancer detection more accessible and affordable, and to improve the chances of successful treatment.

Accuray Incorporated is a radiation oncology company that develops, manufactures, and sells radiation therapy systems and software for the treatment of cancer. Accuray's products are used by radiation oncologists to deliver precise and effective radiation therapy treatments to patients with a variety of cancers, including prostate cancer, breast cancer, lung cancer, and brain cancer. Accuray's mission is to expand the curative power of radiation therapy to improve as many lives as possible.

Viz.ai is an AI-powered care coordination platform that helps providers improve patient outcomes. The platform uses advanced algorithms to analyze medical imaging data and provide real-time insights and automated assessments to accelerate diagnosis and treatment. Viz.ai's solutions are used by hospitals and health systems across the country to improve care for patients with a variety of conditions, including stroke, heart disease, and cancer.

Beacon Biosignals provides an EEG neurobiomarker platform that is designed to accelerate clinical trials and enable new treatments for patients with neurological and psychiatric diseases. Their platform is powered by machine learning and a world-class clinico-EEG database, which allows them to analyze existing EEG data for insights into mechanisms, PK/PD, and patient stratification. This information can be used to guide further development efforts, optimize clinical trials, and enhance understanding of treatment efficacy.

Butterfly iQ3 is a handheld, whole-body ultrasound device that provides clear and detailed images for a variety of medical applications. It is the third-generation probe from Butterfly Network, and it features double the processing power and clearer images than its predecessors. Butterfly iQ3 is also equipped with real-time AI, which can help clinicians to identify and diagnose medical conditions more quickly and accurately. The device is lightweight and portable, making it easy to use in a variety of settings, including the clinic, the hospital, and the field. Butterfly iQ3 is a valuable tool for clinicians who want to improve the quality of care they provide to their patients.

Cleerly is a digital healthcare company transforming the way clinicians approach the treatment of heart disease. Our clinically-proven, AI-based digital care platform works with coronary computed tomography angiography (CCTA) imaging to help clinicians precisely identify and define atherosclerosis earlier, so they can provide personalized, life-saving treatment plans for all patients throughout their care continuum. We measure atherosclerosis - plaque build-up in the heart's arteries - not indirect markers such as risk factors and symptoms of disease. Our AI-enabled digital care pathway offers simpler, faster, more accurate heart disease evaluation and reporting that's tailored to each stakeholder, improving overall clinical and financial outcomes.

proudP is a mobile application designed to help individuals assess symptoms related to Benign Prostatic Hyperplasia (BPH) from the comfort of their homes. The app offers a simple and private urine flow test that can be conducted using just a smartphone. Users can track their symptoms, generate personalized reports, and share data with their healthcare providers for tailored treatments. proudP aims to empower users to take control of their urinary health by providing an affordable and convenient at-home testing solution.

NeuProScan is an AI platform designed for the early detection of pre-clinical Alzheimer's from MRI scans. It utilizes AI technology to predict the likelihood of developing Alzheimer's years in advance, helping doctors improve diagnosis accuracy and optimize the use of costly PET scans. The platform is fully customizable, user-friendly, and can be run on devices or in the cloud. NeuProScan aims to provide patients and healthcare systems with valuable insights for better planning and decision-making.

Linus Health is a next-generation digital cognitive assessment platform that enables earlier detection and intervention in brain health. It brings the power of AI to long-trusted cognitive tests, delivering rich insights and actionable clinical guidance. Linus Health's technology has been validated in over 20 published studies and is used by leading organizations to transform their approach to brain health.

MediNav is a medical assistant tool that learns and reduces documentation time for healthcare professionals. It is not just a medical dictation software but an assistant based on a complex algorithm that retains, notes, extracts medical information, and continuously learns. It helps in reducing costs by minimizing the need for additional staff during consultations or transcription, allowing more time for patients to be served, and ensuring faster delivery of imaging results to satisfied clients. MediNav is primarily used in Romanian and is expanding to support other European languages like German, Spanish, and Polish. It leverages cutting-edge speech recognition technology combined with natural language processing to achieve high accuracy. The tool improves through self-correction and adapts to different accents over time. It also enables collaboration among healthcare professionals using a secure federated learning approach without moving data between clinics.

Medlabreport.com is an AI-powered platform that helps users understand their medical exam results easily. By uploading a file, users receive a comprehensive report within 5 minutes, focusing on personalized insights based on symptoms, age, and other factors. The platform's advanced AI analyzes symptoms, provides recommendations, and prioritizes focus areas. While the reports are not a substitute for licensed medical diagnosis, they offer a fast second opinion and complementary perspective to traditional healthcare. Users can take control of their health by accessing easy-to-understand reports that may help them identify potential health issues sooner.

Microsure is a company that develops microsurgical robots to help surgeons perform complex procedures with greater precision and dexterity. Their flagship product, MUSA, is a robot-assisted microsurgery platform that enables surgeons to operate on the smallest anatomical structures with high precision and enhanced dexterity. Microsure's mission is to leave no patient in need of microsurgery untreated.

Leny.ai is an AI-powered medical assistant designed to provide instant support to medical professionals and patients. It offers features such as differential diagnosis, treatment plan drafting, discharge instructions, referral letters, and lab value analysis. Leny.ai aims to streamline healthcare processes, save time, and provide reliable and accurate medical information. The platform is still in beta mode and continuously improving to offer more accurate responses. It is focused on data security and privacy, although not currently HIPAA compliant. Leny.ai is free of charge at present and plans to transition to a subscription-based model in the future.

Abridge is an enterprise-grade AI platform for clinical conversations, integrated directly inside Epic. It transforms patient-clinician conversations into structured clinical notes in real-time, powered by advanced generative AI technology. Abridge saves hours of time-consuming documentation per clinician every month, provides clinically accurate summaries and medical terms across specialties, recognizes and takes accurate notes across a wide range of languages, and creates complete, highly accurate, structured clinical note drafts. The platform aims to return time to healthcare teams, clarity to patients, and efficiencies to healthcare systems, ultimately reducing burnout among clinicians.

Oatmeal Health is an AI-enabled platform that focuses on cancer screening and clinical trials. The platform seamlessly integrates AI technology with dedicated on-site and virtual care teams to provide evidence-based cancer screening models for Community Health Centers. Oatmeal Health aims to improve patient health, lower the overall cost of cancer care, and generate revenue through fee-for-service and value-based reimbursements. The platform offers AI risk assessments, care navigation, and advanced diagnostic screenings to support patients and track outcomes, ultimately aiming for early cancer detection and saving lives.

Freenome is a healthcare company that uses artificial intelligence and multiomics technology to detect cancer in its earliest stages through a simple blood draw. The company's mission is to make early cancer detection more accessible and affordable, and to improve the chances of successful treatment.

Galleri is a multi-cancer early detection test that uses a single blood draw to screen for over 50 types of cancer. It is recommended for adults aged 50 or older who are at an elevated risk for cancer. Galleri is not a diagnostic test and does not detect all cancers. A positive result requires confirmatory diagnostic evaluation by medically established procedures (e.g., imaging) to confirm cancer.

GRAIL is a healthcare company innovating to solve medicine’s most important challenges. Our team of leading scientists, engineers and clinicians are on an urgent mission to detect cancer early, when it is more treatable and potentially curable. GRAIL's Galleri® test is a first-of-its-kind multi-cancer early detection (MCED) test that can detect a signal shared by more than 50 cancer types and predict the tissue type or organ associated with the signal to help healthcare providers determine next steps.

Freenome is a healthcare company that uses artificial intelligence and multiomics technology to detect cancer in its earliest stages through a simple blood draw. The company's mission is to make early cancer detection more accessible and affordable, and to improve the chances of successful treatment.

iCAD is an AI-powered application designed for cancer detection, specifically focusing on breast cancer. The platform offers a suite of solutions including Detection, Density Assessment, and Risk Evaluation, all backed by science, clinical evidence, and proven patient outcomes. iCAD's AI-powered solutions aim to expose the hiding place of cancer, providing certainty and peace of mind, ultimately improving patient outcomes and saving more lives.

Caption Care provides accessible cardiac ultrasounds to detect heart disease earlier, when it's easier and more cost-effective to manage. The result: better patient outcomes, more accurate risk scoring, and reduced downstream costs.

Lunit Inc. is a leading provider of AI-powered cancer screening and treatment solutions. The company's mission is to conquer cancer through AI by developing innovative technologies that can help detect and treat cancer earlier and more effectively. Lunit's AI solutions are used by hospitals and clinics around the world to improve the accuracy and efficiency of cancer diagnosis and treatment.

Galleri is a multi-cancer early detection test that uses a single blood draw to screen for over 50 types of cancer. It is recommended for adults aged 50 or older who are at an elevated risk for cancer. Galleri is not a diagnostic test and does not detect all cancers. A positive result requires confirmatory diagnostic evaluation by medically established procedures (e.g., imaging) to confirm cancer.

The National Cancer Institute's Center for Biomedical Informatics and Information Technology (CBIIT) provides a comprehensive suite of tools, resources, and training to support cancer data science research. These resources include data repositories, analytical tools, data standards, and training materials. CBIIT also develops and maintains the NCI Thesaurus, a comprehensive vocabulary of cancer-related terms, and the Cancer Data Standards Registry and Repository (caDSR), a repository of cancer data standards. CBIIT's mission is to accelerate the pace of cancer research by providing researchers with the tools and resources they need to access, analyze, and share cancer data.

FutureKid.ai is an AI-powered application that allows users to generate pictures of their future kids using just one image of each parent. The application uses advanced AI algorithms to create realistic HD images that provide a glimpse into the user's future family. The process is automated, ensuring user privacy by deleting all data from servers within 24 hours. FutureKid.ai is a German-based company that values user privacy and offers a unique way to visualize potential future offspring.

GRAIL is a healthcare company innovating to solve medicine’s most important challenges. Our team of leading scientists, engineers and clinicians are on an urgent mission to detect cancer early, when it is more treatable and potentially curable. GRAIL's Galleri® test is a first-of-its-kind multi-cancer early detection (MCED) test that can detect a signal shared by more than 50 cancer types and predict the tissue type or organ associated with the signal to help healthcare providers determine next steps.

SeeYourBabyAI is an AI-powered platform that offers a unique service to predict the appearance of your future baby based on photos of you and your partner. By leveraging advanced AI technology, the platform generates realistic images of potential sons and daughters with a high level of accuracy. Users can upload their photos, receive multiple AI-generated baby photos, and share them with family and friends. The platform focuses on precision, respects ethnic backgrounds, ensures privacy through encryption, and provides high-resolution, realistic photos for a one-time payment. SeeYourBabyAI aims to provide users with a heartwarming and fun experience of visualizing their future children.

Mapmygenome is an AI-powered platform that offers DNA testing products for health, fitness, and beauty. It provides personalized insights based on genetic analysis to help individuals make informed decisions about their health, wellness, and lifestyle choices. With over 23 years of genomics experience and the latest sequencing technology, Mapmygenome aims to empower users to take proactive steps towards improving their overall well-being.

Synthace is a software and expertise platform designed for Discovery Biology Teams to streamline and optimize their experiments in assay development, media optimization, and purification process development. The platform offers software solutions, training, and on-site support from specialists to help scientists conduct experiments more efficiently and effectively. By leveraging multifactorial methods and automation, Synthace aims to accelerate drug discovery processes and deliver faster, definitive results.

Protocol Pal is a website designed to help users with building protocols. It is a platform created by Basam Alasaly, Ocean Explains, and Tkruer. The website aims to assist individuals in creating structured protocols efficiently. Users can benefit from the tool's features to streamline their protocol development process. Protocol Pal is a valuable resource for anyone looking to organize and document their procedures effectively.

Proscia is a leading provider of digital pathology solutions for the modern laboratory. Its flagship product, Concentriq, is an enterprise pathology platform that enables anatomic pathology laboratories to achieve 100% digitization and deliver faster, more precise results. Proscia also offers a range of AI applications that can be used to automate tasks, improve diagnostic accuracy, and accelerate research. The company's mission is to perfect cancer diagnosis with intelligent software that changes the way the world practices pathology.

AskEllyn.ai is a supportive platform designed for individuals diagnosed with breast cancer. It offers a wealth of knowledge, wisdom, and advice shared by survivors to empower and comfort those on a similar journey. The website features a unique AI companion, AskEllyn chatbot, which provides judgment-free, empathetic support to users in multiple languages. The platform is backed by The Lyndall Project, a non-profit organization dedicated to enhancing patient experiences through AI-driven conversational care.

Oncora Medical is a healthcare technology company that provides software and data solutions to oncologists and cancer centers. Their products are designed to improve patient care, reduce clinician burnout, and accelerate clinical discoveries. Oncora's flagship product, Oncora Patient Care, is a modern, intelligent user interface for oncologists that simplifies workflow, reduces documentation burden, and optimizes treatment decision making. Oncora Analytics is an adaptive visual and backend software platform for regulatory-grade real world data analytics. Oncora Registry is a platform to capture and report quality data, treatment data, and outcomes data in the oncology space.

Owkin is a full-stack AI biotech company that integrates the best of human and artificial intelligence to deliver better drugs and diagnostics at scale. By understanding complex biology through AI, Owkin identifies new treatments, de-risks and accelerates clinical trials, and builds diagnostic tools to reduce time to impact for patients.

BetterMedicine is an AI software designed for cancer diagnostics and detection. It offers AI-powered solutions to enhance patient outcomes and drive efficiency in radiology workflows. The software is expertly designed by medical professionals and AI specialists, providing trusted and clinically validated solutions. BetterMedicine aims to address inefficiencies in radiology by integrating AI-powered software for detecting lesions on CT scans seamlessly into the workflow, thereby improving efficiency and reducing the risk of oversight. The application focuses on improving patient outcomes, reducing errors, and enhancing the wellbeing of radiology professionals.

iCAD is an AI-powered application designed for cancer detection, specifically focusing on breast cancer. The platform offers a suite of solutions including Detection, Density Assessment, and Risk Evaluation, all backed by science, clinical evidence, and proven patient outcomes. iCAD's AI-powered solutions aim to expose the hiding place of cancer, providing certainty and peace of mind, ultimately improving patient outcomes and saving more lives.

Paige is a leading AI company revolutionizing pathology with next-generation technology. They provide diagnostic and biomarker AI, predictive analytics technology, and AI-assisted applications to support cancer detection, subtyping, and molecular biomarker discovery from tissue samples. Paige offers a range of AI suites for prostate, breast, colon, and PanCancer, as well as the innovative Paige Alba™ multi-modal co-pilot. Their advanced AI technology and services help streamline AI development, optimize existing applications, and drive groundbreaking advancements in cancer care.

Oncora Medical is an AI-powered platform that revolutionizes oncology care management. The platform offers a Clinical Data Platform for automating document generation and enhancing registry informatics. It provides AI-enabled case findings, revenue cycle management solutions, and cancer registry automation. Oncora's comprehensive AI solutions streamline workflows, improve outcomes, and capture revenue through intelligent automation. Trusted by top healthcare organizations worldwide, Oncora empowers healthcare organizations to achieve remarkable results in oncology care.

MediNav is a medical assistant tool that learns and reduces documentation time for healthcare professionals. It is not just a medical dictation software but an assistant based on a complex algorithm that retains, notes, extracts medical information, and continuously learns. It helps in reducing costs by minimizing the need for additional staff during consultations or transcription, allowing more time for patients to be served, and ensuring faster delivery of imaging results to satisfied clients. MediNav is primarily used in Romanian and is expanding to support other European languages like German, Spanish, and Polish. It leverages cutting-edge speech recognition technology combined with natural language processing to achieve high accuracy. The tool improves through self-correction and adapts to different accents over time. It also enables collaboration among healthcare professionals using a secure federated learning approach without moving data between clinics.

LifeSciencesIntelligence is a comprehensive online platform that delivers the latest news, insights, and resources in the fields of life sciences, biotechnology, genetics/genomics, and pathology. It serves as a valuable hub for professionals, researchers, and industry experts to stay informed about cutting-edge advancements and emerging trends in these domains.

Nucleai is an AI-driven spatial biomarker analysis tool that leverages military intelligence-grade geospatial AI methods to analyze complex cellular interactions in a patient's biopsy. The platform offers a first-of-its-kind multimodal solution by ingesting images from various modalities and delivering actionable insights to optimize biomarker scoring, predict response to therapy, and revolutionize disease diagnosis and treatment.